A phase II Southwest Oncology Group study of cisplatin and continuous infusion vinblastine in the treatment of advanced soft tissue sarcoma.
Bone and soft tissue sarcomas currently comprise 1% of adult malignancies and 15% of pediatric malignancies [1]. While doxorubicin and ifosfamide are active agents, no significant impact on survival has been observed. More active regimes are required in sarcoma. This trial studied cisplatin and a 5 day continuous infusion of vinblastine for patients who had had disease progression of advanced soft tissue sarcoma after a doxorubicin based regimen. Between July 1983 and October 1986, 20 patients entered the study. There were no treatment related deaths. Seven patients required dose adjustment for neutropenia. No responses were observed.